- Home
- AMED vs NAMS Comparison
AMED vs NAMS Comparison
Compare AMED & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMED
- NAMS
- Stock Information
- Founded
- AMED 1982
- NAMS 2019
- Country
- AMED United States
- NAMS Netherlands
- Employees
- AMED N/A
- NAMS N/A
- Industry
- AMED Medical/Nursing Services
- NAMS Biotechnology: Pharmaceutical Preparations
- Sector
- AMED Health Care
- NAMS Health Care
- Exchange
- AMED Nasdaq
- NAMS Nasdaq
- Market Cap
- AMED 3.0B
- NAMS 2.5B
- IPO Year
- AMED N/A
- NAMS N/A
- Fundamental
- Price
- AMED $97.46
- NAMS $17.96
- Analyst Decision
- AMED Hold
- NAMS Strong Buy
- Analyst Count
- AMED 6
- NAMS 8
- Target Price
- AMED $100.80
- NAMS $42.88
- AVG Volume (30 Days)
- AMED 318.8K
- NAMS 893.6K
- Earning Date
- AMED 07-23-2025
- NAMS 08-06-2025
- Dividend Yield
- AMED N/A
- NAMS N/A
- EPS Growth
- AMED N/A
- NAMS N/A
- EPS
- AMED 2.72
- NAMS N/A
- Revenue
- AMED $2,371,691,000.00
- NAMS $47,140,000.00
- Revenue This Year
- AMED $6.29
- NAMS N/A
- Revenue Next Year
- AMED $5.25
- NAMS N/A
- P/E Ratio
- AMED $36.05
- NAMS N/A
- Revenue Growth
- AMED 5.34
- NAMS 586.97
- 52 Week Low
- AMED $82.15
- NAMS $14.06
- 52 Week High
- AMED $98.95
- NAMS $27.29
- Technical
- Relative Strength Index (RSI)
- AMED 68.15
- NAMS 42.30
- Support Level
- AMED $96.92
- NAMS $20.06
- Resistance Level
- AMED $98.32
- NAMS $21.91
- Average True Range (ATR)
- AMED 0.95
- NAMS 1.41
- MACD
- AMED 0.28
- NAMS -0.20
- Stochastic Oscillator
- AMED 81.18
- NAMS 4.45
About AMED Amedisys Inc
Amedisys Inc is a healthcare services company in the United States. The company brings healthcare to the home through the provision of home healthcare services, hospice services, and high acuity care segment. The Home Health Segment provides skilled nurses, therapists, and aids to patients' homes throughout the United States; the Hospice segment operates many centers designed to provide comfort and support for terminally ill patients; and the High acuity care segment can deliver the essential elements of inpatient hospital, SNF care, and palliative care to patients in their homes. A majority of the company's revenue is derived from the Home Health segment.
About NAMS NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.